JP2021534201A5 - - Google Patents

Info

Publication number
JP2021534201A5
JP2021534201A5 JP2021509893A JP2021509893A JP2021534201A5 JP 2021534201 A5 JP2021534201 A5 JP 2021534201A5 JP 2021509893 A JP2021509893 A JP 2021509893A JP 2021509893 A JP2021509893 A JP 2021509893A JP 2021534201 A5 JP2021534201 A5 JP 2021534201A5
Authority
JP
Japan
Prior art keywords
nucleic acid
acid sequence
administered
approximately
pharmaceutical composition
Prior art date
Application number
JP2021509893A
Other languages
English (en)
Japanese (ja)
Other versions
JP7403852B2 (ja
JP2021534201A (ja
JPWO2020038352A5 (https=
Filing date
Publication date
Priority claimed from CN201810948193.1A external-priority patent/CN110846392A/zh
Priority claimed from PCT/CN2018/103937 external-priority patent/WO2020000641A1/zh
Priority claimed from CN201811221305.XA external-priority patent/CN111073899B/zh
Priority claimed from CN201811230856.2A external-priority patent/CN111068071A/zh
Priority claimed from PCT/CN2019/101538 external-priority patent/WO2020038352A1/en
Application filed filed Critical
Publication of JP2021534201A publication Critical patent/JP2021534201A/ja
Publication of JPWO2020038352A5 publication Critical patent/JPWO2020038352A5/ja
Publication of JP2021534201A5 publication Critical patent/JP2021534201A5/ja
Priority to JP2023205807A priority Critical patent/JP7690713B2/ja
Publication of JP7403852B2 publication Critical patent/JP7403852B2/ja
Application granted granted Critical
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021509893A 2018-08-20 2019-08-20 レーベル遺伝性視神経症を治療するための組成物及び方法 Active JP7403852B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023205807A JP7690713B2 (ja) 2018-08-20 2023-12-06 レーベル遺伝性視神経症を治療するための組成物及び方法

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
CN201810948193.1A CN110846392A (zh) 2018-08-20 2018-08-20 一种重组腺相关病毒或含其的试剂盒及其应用
CN201810948193.1 2018-08-20
CNPCT/CN2018/103937 2018-09-04
PCT/CN2018/103937 WO2020000641A1 (zh) 2018-06-29 2018-09-04 编码人nadh脱氢酶亚单位蛋白的核酸及其应用
CN201811221305.X 2018-10-19
CN201811221305.XA CN111073899B (zh) 2018-10-19 2018-10-19 一种编码人nadh脱氢酶亚单位4蛋白的核酸及其应用
CN201811230856.2A CN111068071A (zh) 2018-10-22 2018-10-22 基因治疗Leber遗传学视神经病变
CN201811230856.2 2018-10-22
CNPCT/CN2018/113799 2018-11-02
PCT/CN2018/113799 WO2020082417A1 (zh) 2018-10-22 2018-11-02 基因治疗Leber遗传性视神经病变
PCT/CN2018/118662 WO2020077756A1 (zh) 2018-10-19 2018-11-30 Nd4蛋白的编码序列及其应用
CNPCT/CN2018/118662 2018-11-30
PCT/CN2019/070461 WO2020037938A1 (zh) 2018-08-20 2019-01-04 一种重组腺相关病毒或含其的试剂盒及其应用
CNPCT/CN2019/070461 2019-01-04
PCT/CN2019/101538 WO2020038352A1 (en) 2018-08-20 2019-08-20 Compositions and methods for treating leber's hereditary optic neuropathy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023205807A Division JP7690713B2 (ja) 2018-08-20 2023-12-06 レーベル遺伝性視神経症を治療するための組成物及び方法

Publications (4)

Publication Number Publication Date
JP2021534201A JP2021534201A (ja) 2021-12-09
JP2021534201A5 true JP2021534201A5 (https=) 2022-08-29
JPWO2020038352A5 JPWO2020038352A5 (https=) 2022-08-29
JP7403852B2 JP7403852B2 (ja) 2023-12-25

Family

ID=74668040

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021509893A Active JP7403852B2 (ja) 2018-08-20 2019-08-20 レーベル遺伝性視神経症を治療するための組成物及び方法
JP2023205807A Active JP7690713B2 (ja) 2018-08-20 2023-12-06 レーベル遺伝性視神経症を治療するための組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023205807A Active JP7690713B2 (ja) 2018-08-20 2023-12-06 レーベル遺伝性視神経症を治療するための組成物及び方法

Country Status (8)

Country Link
US (2) US11352645B2 (https=)
EP (1) EP3840785A4 (https=)
JP (2) JP7403852B2 (https=)
KR (1) KR20210068014A (https=)
CN (1) CN112584874A (https=)
AU (1) AU2019323434A1 (https=)
CA (1) CA3109432A1 (https=)
SG (1) SG11202101032VA (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240014102A (ko) 2018-06-29 2024-01-31 우한 뉴로프스 바이오테크놀로지 리미티드 컴퍼니 레버 유전성 시신경병증의 치료를 위한 조성물 및 방법
CA3109432A1 (en) 2018-08-20 2020-02-27 Wuhan Neurophth Biotechnology Limited Company Compositions and methods for treating leber's hereditary optic neuropathy
US20210100856A1 (en) * 2019-09-11 2021-04-08 Adverum Biotechnologies, Inc. Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept
CN113025633B (zh) * 2019-12-09 2024-08-27 武汉纽福斯生物科技有限公司 编码人nadh脱氢酶亚单位1蛋白的核酸及其应用
CA3228344A1 (en) * 2021-08-06 2023-02-09 Wuhan Neurophth Biotechnology Limited Company Composition and method for treating leber's hereditary optic neuropathy caused by nd4 mutation
CN116789772A (zh) * 2022-03-18 2023-09-22 北京安龙生物医药有限公司 Aav5扩容衣壳突变体及其扩容检测方法
WO2024144330A1 (ko) * 2022-12-29 2024-07-04 주식회사 엣진 레베르 유전성 시신경병증의 미토콘드리아 염기 변이 교정 시스템
CN118320132A (zh) * 2024-04-26 2024-07-12 首都医科大学附属北京友谊医院 重组腺相关病毒rAAV2/Rec2作为胰腺靶向性载体的应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3625214A (en) 1970-05-18 1971-12-07 Alza Corp Drug-delivery device
US4906474A (en) 1983-03-22 1990-03-06 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
US4789734A (en) 1985-08-06 1988-12-06 La Jolla Cancer Research Foundation Vitronectin specific cell receptor derived from mammalian mesenchymal tissue
EP0545913B1 (en) 1986-08-18 1999-02-24 Emisphere Technologies, Inc. Delivery systems for pharmacological agents
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5811128A (en) 1986-10-24 1998-09-22 Southern Research Institute Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
EP0678034B1 (en) 1993-01-11 1999-05-26 Dana Farber Cancer Institute Inducing cytotoxic t lymphocyte responses
AU2668897A (en) 1996-04-19 1997-11-12 Genetic Therapy, Inc. Gene therapy involving concurrent and repeated administration of adenoviruses and immunosuppressive agents
US6207392B1 (en) 1997-11-25 2001-03-27 The Regents Of The University Of California Semiconductor nanocrystal probes for biological applications and process for making and using such probes
US20020132978A1 (en) * 2000-03-21 2002-09-19 Hans-Peter Gerber VEGF-modulated genes and methods employing them
CA2442670A1 (en) * 2001-04-13 2002-10-24 The Trustees Of The University Of Pennsylvania Method of treating or retarding the development of blindness
EP1751275B1 (en) 2004-06-01 2017-08-16 Avigen, Inc. Compositions and methods to prevent aav vector aggregation
US20130022979A1 (en) * 2005-04-18 2013-01-24 Genesis Genomics Inc. 3.4kb MITOCHONDRIAL DNA DELETION FOR USE IN THE DETECTION OF CANCER
ES2541771T3 (es) 2005-05-03 2015-07-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Expresión de una proteína mitocondrial mediante un enfoque alotópico mejorado
CA2667705A1 (en) 2006-10-23 2008-05-29 University Of Florida Research Foundation, Inc. Suppression of mitochondrial oxidative stress
EP2121914B1 (en) * 2007-02-16 2014-08-20 John Guy Mitochondrial nucleic acid delivery systems
EP2565649B1 (en) * 2007-06-20 2015-04-15 Galapagos N.V. Molecular targets and compounds, and methods to identify the same, useful in the treatment of bone and joint degenerative diseases
ES2563984T3 (es) * 2008-10-22 2016-03-17 Quark Pharmaceuticals, Inc. Métodos para el tratamiento de trastornos oculares
DK2529020T3 (en) 2010-01-28 2018-08-06 Childrens Hospital Philadelphia SCALABLE PREPARATION PLATF FOR CLEANING VIRAL VECTORS AND CLEANED VIRAL VECTORS FOR USE IN GENTHERAPY
CN102517304B (zh) 2011-12-16 2013-08-28 中国农业科学院生物技术研究所 重组葡萄糖氧化酶的优化基因及其表达载体和应用
US20160289674A1 (en) * 2012-04-02 2016-10-06 Moderna Therapeutics, Inc. Modified polynucleotides for the production of membrane proteins
CN102634527B (zh) 2012-04-11 2013-11-06 华中科技大学同济医学院附属同济医院 重组人nadh脱氢酶亚单位4基因及其表达载体构建方法
TWI690322B (zh) 2012-10-02 2020-04-11 法商傳斯堅公司 含病毒的調配物及其使用
US10493141B2 (en) 2014-09-17 2019-12-03 The University Of Iowa Research Foundation Viral RNA segments as immunomodulatory agents and vaccine components
CN104450747B (zh) * 2014-09-23 2018-02-09 武汉纽福斯生物科技有限公司 用于治疗Leber遗传性视神经病变的重组腺相关病毒‑NADH脱氢酶亚单位4基因全长以及药剂
EP3322297B1 (en) 2015-07-13 2024-12-04 Sangamo Therapeutics, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
CA2973885A1 (en) * 2016-07-21 2018-01-21 Stealth Biotherapeutics Corp Therapeutic compositions including mitochondrial-targeted creatine compounds and uses thereof to treat and prevent mitochondrial diseases and conditions
WO2018102672A1 (en) * 2016-12-04 2018-06-07 Alavi Khorassani Moghadam Marcel Victor Methods for treating diseases related to mitochondrial stress
US20180207293A1 (en) * 2017-01-25 2018-07-26 2C Tech Corp. Nanoparticles for sustained ophthalmic drug delivery and methods of use
EP3441069B1 (en) * 2017-08-11 2023-04-05 Unity Biotechnology, Inc. Treatment of diabetic retinopathy using pharmaceutical agents that eliminate senescent cells
US20210163898A1 (en) * 2018-04-16 2021-06-03 The Children's Hospital Of Philadelphia Mitochondrial rna import for treating mitochondrial disease
CN112384625A (zh) * 2018-06-11 2021-02-19 珍视生物股份公司 重组aav载体及其使用方法
CN111068071A (zh) 2018-10-22 2020-04-28 武汉纽福斯生物科技有限公司 基因治疗Leber遗传学视神经病变
WO2020010491A1 (zh) 2018-07-09 2020-01-16 武汉纽福斯生物科技有限公司 编码人nadh脱氢酶亚单位4蛋白的核酸及其应用
CN110846392A (zh) 2018-08-20 2020-02-28 武汉纽福斯生物科技有限公司 一种重组腺相关病毒或含其的试剂盒及其应用
KR20240014102A (ko) 2018-06-29 2024-01-31 우한 뉴로프스 바이오테크놀로지 리미티드 컴퍼니 레버 유전성 시신경병증의 치료를 위한 조성물 및 방법
WO2020001657A1 (en) 2018-06-29 2020-01-02 Wuhan Neurophth Biological Technology Limited Company Compositions and methods for treating leber's hereditary optic neuropathy
WO2020000641A1 (zh) 2018-06-29 2020-01-02 武汉纽福斯生物科技有限公司 编码人nadh脱氢酶亚单位蛋白的核酸及其应用
CN111073899B (zh) 2018-10-19 2021-01-01 武汉纽福斯生物科技有限公司 一种编码人nadh脱氢酶亚单位4蛋白的核酸及其应用
CA3109432A1 (en) 2018-08-20 2020-02-27 Wuhan Neurophth Biotechnology Limited Company Compositions and methods for treating leber's hereditary optic neuropathy
WO2020038352A1 (en) 2018-08-20 2020-02-27 Wuhan Neurophth Biological Technology Limited Company Compositions and methods for treating leber's hereditary optic neuropathy
CN113025633B (zh) 2019-12-09 2024-08-27 武汉纽福斯生物科技有限公司 编码人nadh脱氢酶亚单位1蛋白的核酸及其应用

Similar Documents

Publication Publication Date Title
JP2021534201A5 (https=)
Lipworth et al. Effect of ciclesonide and fluticasone on hypothalamicpituitary-adrenal axis function in adults with mild-to-moderate persistent asthma
Davies et al. Once-daily mometasone furoate nasal spray: efficacy and safety of a new intranasal glucocorticoid for allergic rhinitis
Kelly Comparison of inhaled corticosteroids
KR20010110803A (ko) 약제학적 조성물
JPWO2020038352A5 (https=)
US20110144072A1 (en) Antiglucocorticoid Therapy for the Prevention of Neurological Damage in Premature Infants
Mehdipour et al. Role of corticosteroids in oral lesions
Helfer et al. Corticosteroids and adrenal suppression: characterising and avoiding the problem
KR910011279A (ko) 스테로이드 요법에 의한 부작용을 경감 또는 예방방법 및 이를 위한 조성물
Ververeli et al. Oral corticosteroid-sparing effects of inhaled corticosteroids in the treatment of persistent and acute asthma
Myers Treatment of multiple sclerosis with ACTH and corticosteroids
IL312514A (en) Corticosteroid reduction in treatment with anti-cd38 antibodies
IL312515A (en) Bispecific cd16a binders
JPWO2023091887A5 (https=)
Smith et al. A controlled trial of beclomethasone dipropionate for asthma
Shapiro Corticosteroids in the treatment of allergic disease: principles and practice
JPWO2022074123A5 (https=)
JPWO2023017252A5 (https=)
Ono et al. Effect of peripherally derived steroid hormones on the expression of steroidogenic enzymes in the rat choroid plexus
JPWO2022223770A5 (https=)
Sturgess Rational use of corticosteroids in small animals
JPWO2022238479A5 (https=)
Newton et al. Manipulation by corticotropin and cortisol of aldosterone secretion in primary aldosteronism
JPWO2023079494A5 (https=)